Oral hormonal contraception (OHC) is one of the most effective reversible method of contraception. OHC prevents pregnancy, but also effects other organs and organ systems. The purpose of this thesis is to analyze the suspected adverse reactions of oral hormonal contraceptives for systemic use (ATK G03A) reported to the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) in the period from June 11, 1993 to February 2, 2021. In total, 515 suspected adverse drug reactions from G03A group were analyzed and data were proccesed according to the patient's age and gender, seriousness, outcome, reporter, affiliation of adverse reactions according to the Medical Dictionary of Regulatory Affairs (MedDRA) organic system classification and active substance. Also, the frequency of side effects of oral hormonal contraceptives in the total number of reported side effects was analyzed. Most adverse drug reactions were reported by doctors (41,75 %). The largest number of adverse drug reactions was not serious (63,69 %). According to the active substance, the highest number of adverse reactions was reported for the combination of drospirenone and ethinlyestradiol (28,36 %), the combination of gestodene and ethinylestradiol (16,57 %) and ulipristal (11,05 %). The largest number of adverse drug reactions belongs to System organ class (SOC) Reproductive system and breast disorder (14,49 %) and SOC General disorders and administration site conditions (11,98 %). Two most common adverse reactions were headache (4,45 %) and nausea (3,97 %). Comparison with European (EudraVigilance) and global (VigiAccess) database of adverse drug reactions, a match was found in most of the processed data. Although pain is listed as the most common adverse reaction in these databases, this study found that it is not common nationally.